Cohort of 198 coronary artery bypass grafting patients monitored for 1 year with insertable cardiac devices found high incidence of new-onset atrial fibrillation but minimal late burden.
Chronic myeloid leukemia (CML) is one of the success stories among the hematologic malignancies. Now, with decades of data informing its management, it is time to change some of the practices to which...
The ASCO Post
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Systemic biases and industry influence have undermined the movement's foundational principles, potentially compromising patient care across multiple specialties.
On September 25, the U.S. Food and Drug Administration (FDA) removed the Risk Evaluation and Mitigation Strategies (REMS) program for vandetanib, according to an announcement from the agency.